<DOC>
	<DOCNO>NCT00541866</DOCNO>
	<brief_summary>This study evaluate safety tolerability voreloxin injection combination cytarabine patient relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Safety Tolerability Study Voreloxin Cytarabine Combination Acute Myeloid Leukemia Humans</brief_title>
	<detailed_description>Other objective study include : 1 . Assess antileukemic activity 2 . Characterize pharmacokinetic profile 3 . Evaluate potential biomarkers</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Relapsed refractory AML subtypes , except acute promyelocytic leukemia ( APL ) History myocardial infarction within 3 month study treatment History cerebrovascular accident/transient ischemic attack ( CVA/TIA ) within 3 month study treatment Thromboembolic event ( deep vein thrombosis pulmonary embolus ) within 28 day study treatment Known intolerance cytarabine know allergy Dsorbitol methanesulfonic acid Please note : There additional inclusion/exclusion criterion study . Please contact study center additional information determine study criterion meet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Cancer</keyword>
	<keyword>AML</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>SNS-595</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Voreloxin</keyword>
</DOC>